Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697943 | 0.77 | THRB (0.41) | THRB | |
| SCHEMBL7401569 | 0.73 | THRB (0.35) | THRB | |
| SCHEMBL30952869 | 0.70 | — | — | |
| SCHEMBL17136209 | 0.70 | — | — | |
| SCHEMBL9650 | 0.70 | — | — | |
| SCHEMBL408235 | 0.70 | — | — | |
| SCHEMBL17238811 | 0.70 | THRB (0.33) | THRB | |
| SCHEMBL333470 | 0.70 | — | — | |
| SCHEMBL321135 | 0.70 | — | — | |
| Hydrogen Peroxide SCHEMBL22401584 | 0.69 | THRB (0.41) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040290-A1 | COMPOSITION, METHOD FOR FORMING RESIST PATTERN AND METHOD FOR FORMING INSULATING FILM | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3747954-A1 | COMPOSITION, RESIST-PATTERN FORMING METHOD, AND INSULATING-FILM FORMING METHOD | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2020-12-09 | — | — | EP | disclosed |
| CN-111630111-A | Composition, method for forming resist pattern, and method for forming insulating film | 三菱瓦斯化学株式会社 | 2020-09-04 | — | — | CN | disclosed |
| WO-2019151403-A1 | COMPOSITION, RESIST-PATTERN FORMING METHOD, AND INSULATING-FILM FORMING METHOD | 三菱瓦斯化学株式会社 | 2019-08-08 | — | — | WO | disclosed |
| US-9809599-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2773619-B1 | NEW ARYL-QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-20160252818-A9 | PRODUCTION METHOD OF SEMICONDUCTOR ELEMENT, AND ION IMPLANTATION METHOD | JSR CORPORATION (JP) | 2016-09-01 | — | — | US | disclosed |
| EP-2707371-B1 | NEW HEXAHYDROPYRROLOIMIDAZOLONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | disclosed |
| EP-2688881-B1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2012020035-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007367-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | AZI2, CDKN1A, TOP2B | THRB 2741/4885 |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | FABP1, FABP4, FABP5 | THRB 1204/4885 |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | THRB 891/4885 |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | THRB 1162/4885 |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | THRB 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.